- Home
- NYC vs BNGO Comparison
NYC vs BNGO Comparison
Compare NYC & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- BNGO
- Stock Information
- Founded
- NYC 2013
- BNGO 2003
- Country
- NYC United States
- BNGO United States
- Employees
- NYC N/A
- BNGO N/A
- Industry
- NYC Real Estate
- BNGO Biotechnology: Laboratory Analytical Instruments
- Sector
- NYC Finance
- BNGO Industrials
- Exchange
- NYC Nasdaq
- BNGO Nasdaq
- Market Cap
- NYC 27.6M
- BNGO 24.3M
- IPO Year
- NYC N/A
- BNGO 2018
- Fundamental
- Price
- NYC $10.45
- BNGO $5.36
- Analyst Decision
- NYC
- BNGO Hold
- Analyst Count
- NYC 0
- BNGO 3
- Target Price
- NYC N/A
- BNGO $60.00
- AVG Volume (30 Days)
- NYC 8.2K
- BNGO 265.7K
- Earning Date
- NYC 03-31-2025
- BNGO 03-04-2025
- Dividend Yield
- NYC N/A
- BNGO N/A
- EPS Growth
- NYC N/A
- BNGO N/A
- EPS
- NYC N/A
- BNGO N/A
- Revenue
- NYC $62,060,000.00
- BNGO $33,334,000.00
- Revenue This Year
- NYC N/A
- BNGO N/A
- Revenue Next Year
- NYC $3.18
- BNGO $6.18
- P/E Ratio
- NYC N/A
- BNGO N/A
- Revenue Growth
- NYC N/A
- BNGO N/A
- 52 Week Low
- NYC $5.46
- BNGO $4.75
- 52 Week High
- NYC $12.52
- BNGO $81.00
- Technical
- Relative Strength Index (RSI)
- NYC 50.89
- BNGO 34.06
- Support Level
- NYC $10.50
- BNGO $5.05
- Resistance Level
- NYC $12.52
- BNGO $6.32
- Average True Range (ATR)
- NYC 0.68
- BNGO 0.50
- MACD
- NYC -0.04
- BNGO 0.31
- Stochastic Oscillator
- NYC 22.18
- BNGO 38.85
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.